Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tissue ablation by cryogenic destruction is a procedural technique in which localized tissue is deliberately destroyed using very low temperatures. Typically achieved via cryoprobes cooled with gases such as argon or nitrogen, this process results in cellular death through mechanisms that include formation of intracellular and extracellular ice crystals, cellular dehydration, membrane rupture, protein denaturation, ischemia secondary to vascular coagulation, and apoptosis. The method is most commonly used for tumor ablation (including prostate and renal cancers) and for cardiac arrhythmia procedures such as ablation of arrhythmogenic foci in the heart. It is not a molecule, receptor, enzyme, or canonical therapeutic target, but an interventional procedure used across multiple medical specialties[2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tissue ablation by cryogenic destruction.